The IPECAD Alzheimer’s disease model (Green et al, 2019) has been developed by the IPECAD Modelling Group as a framework to model disease progression across Alzheimer’s disease (AD) and to assess the costs and outcomes associated with the condition, and the cost-effectiveness of interventions for people affected by AD, using the scenario of a future disease modifying therapies (DMT) for people with mild cognitive impairment (MCI) due to AD.
A description of the model (version 1.0) entitled “Assessing cost-effectiveness of early intervention in Alzheimer’s disease: An open-source modeling framework” is published open-access in the journal Alzheimer’s and Dementia: the journal of the Alzheimer’s Association (Alzheimers Dement 2019 Oct;15(10):1309-1321 doi: 10.1016/j.jalz.2019.05.004 or PubMed).
You can use this open-source model for free under the Creative Commons Attribution-ShareAlike 4.0 International Public License.
We host a version history developed by the IPECAD Modelling Group below.
We provide a listing of self-reported external applications of the model below to endorse transparency.
Request a download link
Citations of Green et al. Alzheimers Dement. 2019 Oct;15(10):1309-1321: https://pubmed.ncbi.nlm.nih.gov/31402324/#citedby
2021 Aug 5: IPECAD open-source model was described in a cross-comparison to other models by ICER. https://icer.org/news-insights/press-releases/icer-publishes-final-evidence-report-and-policy-recommendations-on-aducanumab-for-alzheimers-disease/
2020 October: Jun H, Cho SK, Aliyev ER, Mattke S, Suen SC. How Much Value Would a Treatment for Alzheimer’s Disease Offer? Cost-Effectiveness Thresholds for Pricing a Disease-Modifying Therapy. Curr Alzheimer Res. 2020 Dec 3. doi: 10.2174/1567205017666201203121907. PMID: 33272181
PLANNED: 2021 Nov 8: present IPECAD open-source model on ISPOR Open Source Models journal club.
2020 October (advisory): Bengt Winblad has provided general advise for Grifols International – AMBAR commercial Development who have requested the IPECAD model version 1.0.
2020 May-August (education): Ron Handels guided two master students who have applied the IPECAD model version 1.0 in their internship (Health, Policy and Management master’s program at Maastricht University).
2019 Oct (publication): publication on IPECAD open-sourcemodel 1.0 (Alzheimers Dement. 2019 Oct;15(10):1309-1321. https://doi.org/10.1016/j.jalz.2019.05.004).
2019 Jul 1 (conference): oral presentation at AAIC conference on IPECAD open-source model. Colin Green, Ron Handels, Anders Gustavsson, Anders Wimo, Anders Skoldunger, Bengt Winblad, Linus Jonsson. O5-08-04: A NEW OPEN-SOURCE MODELING FRAMEWORK TO ASSESS COST EFFECTIVENESS OF EARLY INTERVENTION IN ALZHEIMER’S DISEASE. First published: 01 July 2019. https://alz-journals.onlinelibrary.wiley.com/doi/epdf/10.1016/j.jalz.2019.06.4879
2018 Feb 15 (conference): Colin green presented a first draft of the model on the IPECAD conference (8th edition).
2017 May 01 (funding): Ron Handels received support by the Dutch Alzheimer Association (Alzheimer Netherlands) for travel costs for meetings to discuss the IPECAD open-source model. Link: https://www.alzheimer-nederland.nl/onderzoek/fellowships.
2016 June 16: initial discussion on IPECAD open-source model.
1 March 2021
This version was developed as part of the IPECAD modelling workshop challenge 2020 (see https://ipecadgroup.wordpress.com/workshop/). Alongside the Excel version a version was coded in R.
- Addition of input (functionality) on ‘Treatment Discontinuation (waning)’. For Excel version see sheet ‘Inputs’ cell ‘D11’ is 10% corresponding to text “Treatment discontinuation/waning (per year)”.
- Additional reporting by states / disease stages including use of ‘half-cylce correction’ [prior version 1.0 did not report results on disease progression using half-cycle correcction]. For Excel version see for example sheet “Usual Care COhort” cell ‘BV9’.
- Included reporting for results and CEA outputs over a 10-year time horizon. For Excel version see additional tables/reporting on sheets “Usual Care Cohort” and “Treatment Cohort” e.g. from cell ‘DJ19’, and also in sheet “Results” e.g. from cells ‘H11’ & ‘BJ49’.
- Includes additional reporting, on time (person years) in disease stages, with half-cycle correction; to facilitate reporting of trace by severity stage over time. For Excel version see for example in sheet “Outputs” cells ‘X2’ and ‘AW2’.
8 August 2019
Anders Gustavsson (Quantify Research, Sweden; Karolinska Institutet, Sweden)
Colin Green (Biogen UK; University of Exeter, UK; Karolinska Institutet, Sweden)
Ron Handels (Maastricht University, Netherlands; Karolinska Institutet, Sweden)
Linus Jönsson (Karolinska Institutet, Sweden)
Anders Sköldunger (Karolinska Institutet, Sweden)
Anders Wimo (Karolinska Institutet, Sweden)
Bengt Winblad (Karolinska Institutet, Sweden)
Will Herring (RTI Health Solutions, U.S.)
Andreas Karlson (Karolinska Institutet, Sweden) (2019-2020)